Regorafenib

-Regorafenib is an oral multi-kinase inhibitor that targets various protein kinases involved in tumor angiogenesis (blood vessel formation) and oncogenesis (cancer cell growth). It is indicated for the treatment of advanced colorectal cancer, gastrointestinal stromal tumors (GIST), and hepatocellular carcinoma (HCC) in patients who have previously received other treatments.- Regorafenib is a multikinase inhibitor, which targets angiogenic, stromal and oncogenic receptor tyrosine kinase (RTK). Regorafenib shows anti-angiogenic activity due to its dual targeted VEGFR2-TIE2 tyrosine kinase inhibition.

Indications

-Advanced colorectal cancer -Gastrointestinal stromal tumors (GIST) -Hepatocellular carcinoma (HCC) -Colorectal Cancer, Gastrointestinal Stromal Tumors, Hepatocellular carcinoma.

Dosage

-The recommended dosage of Regorafenib may vary depending on the specific type of cancer being treated. It is typically taken orally once daily, with or without food. The dosage should be individualized based on the patient's overall health and tolerance to the drug. -Oral; dose vary , 160mg once daily for 21 days in a 28 days cycle.

Contra-Indications

Regorafenib is contraindicated in patients with: -Hypersensitivity to the active substance or any of the excipients. -Severe hepatic impairment.

Special Precautions

Before starting Regorafenib, healthcare providers should consider: -Monitoring liver function tests regularly -Managing hypertension -Assessing cardiac function -Monitoring for gastrointestinal perforations and fistulasPaediatric: Safety and efficacy in less than 18 years have not been established. Pregnancy: In animal study it is found to be teratogenic, but animal studies are not conclusive. Advise men and women of reproductive potential of the need for effective contraception during treatment and for 2 months after completion of treatment. Lactation: Do not breastfeed during treatment.  Elderly: No overall differences in safety or effectiveness have been observed between elderly and other adult patients.

Side Effects

-Common side effects may include fatigue, hand-foot skin reaction, diarrhea, hypertension, and mucositis. Serious side effects may include hepatotoxicity, hemorrhage, cardiac ischemia, and gastrointestinal perforations. -Hand foot skin reaction, pain, asthenia, fever, fatigue, hypertension, hemorrhage, diarrhea, nausea, vomiting, mucositis, dysphonia, infection, deceased appetite, weight loss, muscle spasm, decrease in blood count

Drug Interactions

Regorafenib may interact with: -CYP3A4 inhibitors/inducers. -Warfarin and other anticoagulants. -Drugs that increase the risk of bleeding. -Drugs that elevate blood pressure. -Avoid using with strong cyp3A4 inducer or inhibitor.